S
4.70
0.12 (2.62%)
| Previous Close | 4.58 |
| Open | 4.61 |
| Volume | 2,365,203 |
| Avg. Volume (3M) | 5,137,222 |
| Market Cap | 1,251,920,640 |
| Price / Book | 6.16 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -0.880 |
| Total Debt/Equity (MRQ) | 43.67% |
| Current Ratio (MRQ) | 3.40 |
| Operating Cash Flow (TTM) | -206.18 M |
| Levered Free Cash Flow (TTM) | -118.45 M |
| Return on Assets (TTM) | -23.84% |
| Return on Equity (TTM) | -71.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Sana Biotechnology, Inc. | Bearish | Mixed |
AIStockmoo Score
0.2
| Analyst Consensus | 2.0 |
| Insider Activity | 0.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.20 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.46% |
| % Held by Institutions | 89.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Flagship Pioneering Inc. | 30 Sep 2025 | 25,001,856 |
| Canada Pension Plan Investment Board | 30 Sep 2025 | 10,175,000 |
| Integral Health Asset Management, Llc | 30 Sep 2025 | 2,000,000 |
| Crestline Management, Lp | 30 Sep 2025 | 1,820,937 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (HC Wainwright & Co., 91.49%) | Buy |
| Median | 7.50 (59.57%) | |
| Low | 6.00 (Wedbush, 27.66%) | Buy |
| Average | 7.50 (59.57%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 4.36 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 06 Jan 2026 | 7.00 (48.94%) | Buy | 4.36 |
| HC Wainwright & Co. | 07 Nov 2025 | 9.00 (91.49%) | Buy | 4.09 |
| Wedbush | 07 Nov 2025 | 6.00 (27.66%) | Buy | 4.09 |
| Citizens | 30 Oct 2025 | 8.00 (70.21%) | Buy | 4.90 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BISHOP HANS EDGAR | 4.06 | - | 6,157 | 24,997 |
| WYRICK SUSAN D. | - | 4.06 | -2,407 | -9,772 |
| Aggregate Net Quantity | 3,750 | |||
| Aggregate Net Value ($) | 15,225 | |||
| Aggregate Avg. Buy ($) | 4.06 | |||
| Aggregate Avg. Sell ($) | 4.06 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WYRICK SUSAN D. | Officer | 05 Jan 2026 | Disposed (-) | 2,407 | 4.06 | 9,772 |
| BISHOP HANS EDGAR | Director | 05 Jan 2026 | Acquired (+) | 6,157 | 4.06 | 24,997 |
| WYRICK SUSAN D. | Officer | 02 Jan 2026 | Option execute | 7,500 | - | - |
| Date | Type | Details |
|---|---|---|
| 07 Jan 2026 | Announcement | Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 08 Dec 2025 | Announcement | Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform |
| 24 Nov 2025 | Announcement | Sana Biotechnology to Present at December 2025 Investor Conferences |
| 06 Nov 2025 | Announcement | Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates |
| 04 Nov 2025 | Announcement | Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |